The report analyzes and forecasts the plasma protein therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of plasma protein therapeutics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major plasma protein therapeutics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of plasma protein therapeutics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of plasma protein therapeutics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global plasma protein therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the plasma protein therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of plasma protein therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Leading companies in the global plasma protein therapeutics market are Octopharma, Baxalta, CSL Behring, and Grifols S.A. Some other companies operating in the global plasma protein therapeutics market are Biotest, China Biologics, Kedrion Inc., and Shire plc.
The global plasma protein therapeutics market has been segmented as follows;
Global Plasma Protein Therapeutics Market by Product
Global Plasma Protein Therapeutics Market by Application
Global Plasma Protein Therapeutics Market by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
Chapter 2 Executive Summary
2.1 Global Plasma Protein Therapeutics Market Snapshot
Chapter 3 Global Plasma Protein Therapeutics Market Revenue Analysis, 2017–2026 (US$ Mn)
3.1 Introduction
3.2 Regulatory Scenario
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunity
3.4 Market Attractiveness Analysis, by Region, 2015
3.5 Porter’s Five Forces Analysis
3.6 Global Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2017–2026 (US$ Mn)
3.6.1 Global Immunoglobulins Market Revenue, 2017–2026 (US$ Mn)
3.6.2 Global Albumin Market Revenue, 2017–2026 (US$ Mn)
3.6.3 Global Coagulation Factors Market Revenue, 2017–2026 (US$ Mn)
3.6.4 Global C1-esterase Inhibitors Market Revenue, 2017–2026 (US$ Mn)
3.6.5 Others (e.g. Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins)
3.7 Global Plasma Protein Therapeutics Market Analysis, By Application, 2017–2026 (US$ Mn)
3.7.1 Global Hemophilia Market Revenue, 2017–2026 (US$ Mn)
3.7.2 Global Primary Immunodeficiency Disorder (PID) Market Revenue, 2017–2026 (US$ Mn)
3.7.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2017–2026 (US$ Mn)
3.7.4 Global Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2017–2026 (US$ Mn)
3.7.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
3.8 Competitive Landscape
3.8.1 Market Positioning of Key Players, 2015
3.8.2 Recommendations
3.9 Pipeline Analysis
3.9.1 Phase 1 and Phase 2 Drugs (Qualitative Analyses)
3.9.2 Phase 3 and Phase 4 Drugs (Quantitative), Forecasts till 2026
Chapter 4 North America Plasma Protein Therapeutics Market Revenue Analysis, 2017–2026 (US$ Mn)
4.1 North America Plasma Protein Therapeutics Market Revenue, By Product Type, 2017–2026 (US$ Mn)
4.1.1 North America Immunoglobulins Market Revenue, 2017–2026 (US$ Mn)
4.1.2 North America Albumin Market Revenue, 2017–2026 (US$ Mn)
4.1.3 North America Coagulation Factors Market Revenue, 2017–2026 (US$ Mn)
4.1.4 North America C1-esterase Inhibitors Market Revenue, 2017–2026 (US$ Mn)
4.1.5 Others
4.2 North America Plasma Protein Therapeutics Market Revenue, By Application, 2017–2026 (US$ Mn)
4.2.1 North America Hemophilia Market Revenue, 2017–2026 (US$ Mn)
4.2.2 North America Primary Immunodeficiency Disorder (PID) Market Revenue, 2017–2026 (US$ Mn)
4.2.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2017–2026 (US$ Mn)
4.2.4 North America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2017–2026 (US$ Mn)
4.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
4.3 North America Plasma Protein Therapeutics Market Revenue, by Country 2017–2026 (US$ Mn)
Chapter 5 Europe Plasma Protein Therapeutics Market Revenue, 2017–2026 US$ Mn)
5.1 Europe Plasma Protein Therapeutics Market Revenue, By Product Type, 2017–2026 (US$ Mn)
5.1.1 Europe Immunoglobulins Market Revenue, 2017–2026 (US$ Mn)
5.1.2 Europe Albumin Market Revenue, 2017–2026 (US$ Mn)
5.1.3 Europe Coagulation Factors Market Revenue, 2017–2026 (US$ Mn)
5.1.4 Europe C1-esterase Inhibitors Market Revenue, 2017–2026 (US$ Mn)
5.1.5 Others
5.2 Europe Plasma Protein Therapeutics Market Revenue, By Application, 2017–2026 (US$ Mn)
5.2.1 Europe Hemophilia Market Revenue, 2017–2026 (US$ Mn)
5.2.2 Europe Primary Immunodeficiency Disorder (PID) Market Revenue, 2017–2026 (US$ Mn)
5.2.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2017–2026 (US$ Mn)
5.2.4 Europe Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2017–2026 (US$ Mn)
5.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
5.3 Europe Plasma Protein Therapeutics Market Revenue, by Country, 2017–2026 (US$ Mn)
Chapter 6 Asia Pacific Plasma Protein Therapeutics Market Revenue Analysis, 2017–2026 (US$ Mn)
6.1 Asia Pacific Plasma Protein Therapeutics Market Revenue, By Product Type, 2017–2026 (US$ Mn)
6.1.1 Asia Pacific Immunoglobulins Market Revenue, 2017–2026 (US$ Mn)
6.1.2 Asia Pacific Albumin Market Revenue, 2017–2026 (US$ Mn)
6.1.3 Asia Pacific Coagulation Factors Market Revenue, 2017–2026 (US$ Mn)
6.1.4 Asia Pacific C1-esterase inhibitors Market Revenue, 2017–2026 (US$ Mn)
6.1.5 Others
6.2 Asia Pacific Plasma Protein Therapeutics Market Revenue, By Application, 2017–2026 (US$ Mn)
6.2.1 Asia Pacific Hemophilia Market Revenue, 2017–2026 (US$ Mn)
6.2.2 Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, 2017–2026 (US$ Mn)
6.2.3 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2017–2026 (US$ Mn)
6.2.4 Asia Pacific Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2017–2026 (US$ Mn)
6.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
6.3 Asia Pacific Plasma Protein Therapeutics Market by Geography, Market Revenue, 2017–2026 (US$ Mn)
Chapter 7 Latin America Plasma Protein Therapeutics Revenue Analysis, 2017–2026 (US$ Mn)
7.1 Latin America Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2017–2026 (US$ Mn)
7.1.1 Latin America Immunoglobulins Market Revenue, 2017–2026 (US$ Mn)
7.1.2 Latin America Albumin Market Revenue, 2017–2026 (US$ Mn)
7.1.3 Latin America Coagulation Factors Market Revenue, 2017–2026 (US$ Mn)
7.1.4 Latin America C1-esterase Inhibitors Market Revenue, 2017–2026 (US$ Mn)
7.1.5 Others
7.2 Latin America Plasma Protein Therapeutics Market Revenue, By Application, 2017–2026 (US$ Mn)
7.2.1 Latin America Hemophilia Market Revenue, 2017–2026 (US$ Mn)
7.2.2 Latin America Primary Immunodeficiency Disorder (PID) Market Revenue, 2017–2026 (US$ Mn)
7.2.3 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2017–2026 (US$ Mn)
7.2.4 Latin America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2017–2026 (US$ Mn)
7.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
7.3 Latin America Plasma Protein Therapeutics Market by Geography, Market Revenue, 2017–2026 (US$ Mn)
Chapter 8 Rest of the World (RoW) Plasma Protein Therapeutics Market Revenue Analysis, 2017–2026 (US$ Mn)
8.1 Rest of World Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2017–2026 (US$ Mn)
8.2 Rest of World Plasma Protein Therapeutics Market Revenue, By Application, 2017–2026 (US$ Mn)
Chapter 9 Company Profiles
9.1 Baxter International
9.1.1 Company Overview
9.1.2 Product Portfolio
9.1.3 Financial Overview
9.1.4 Business Strategies
9.1.5 Recent Development
9.2 Biotest
9.2.1 Company Overview
9.2.2 Product Portfolio
9.2.3 Financial Overview
9.2.4 Recent Development
9.3 CSL Behring
9.3.1 Company Overview
9.3.2 Product Portfolio
9.3.3 Financial Overview
9.3.4 Business Strategies
9.3.5 Recent Development
9.4 China Biologics
9.4.1 Company Overview
9.4.2 Product Portfolio
9.4.3 Financial Overview
9.4.4 Business Strategies
9.4.5 Recent Development
9.5 GRIFOLS, S.A.
9.5.1 Company Overview
9.5.2 Product Portfolio
9.5.3 Financial Overview
9.5.4 Business Strategies
9.5.5 Recent Development
9.6 Kedrion
9.6.1 Company Overview
9.6.2 Product Portfolio
9.6.3 Financial Overview
9.6.4 Recent Development
9.7 Octapharma USA, Inc.
9.7.1 Company Overview
9.7.2 Product Portfolio
9.7.3 Financial Overview
9.7.4 Recent Development
9.8 Shire Plc.
9.8.1 Company Overview
9.8.2 Product Portfolio
9.8.3 Financial Overview
9.8.4 Business Strategies
9.8.5 Recent Development
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers